Caricamento...
Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays
Within the past few years, poly (ADP-ribose) polymerase inhibitors (PARPi) have been added to the standard of care for cancer patients, mainly for those exhibiting specific genomic alterations in the homologous recombination (HR) pathway. Until now, patients who are eligible to receive PARPi have be...
Salvato in:
| Pubblicato in: | Br J Cancer |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Nature Publishing Group UK
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8257604/ https://ncbi.nlm.nih.gov/pubmed/33767416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01295-z |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|